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Autocrine/paracrine role of adrenomedullin in cultured endothelial and
mesangial cells. Adrenomedullin (AM), a potent vasorelaxant and natri-
uretic peptide isolated from human pheochromocytoma, is present in the
kidney and secreted from endothelial cells (EC) and vascular smooth
muscle cells (VSMC), but the functional role of AM is still unclear. To
clarify the significance of AM as a local regulator, we investigated its
secretion and action in cultured cells, and examined the effects of
neutralization using a specific monoclonal antibody against AM. The
prepared antibody directed against the ring structure showed a high
affinity for human and rat AM. Using radioimmunoassay with this
antibody, we found significant secretion from cultured rat mesangial cells
(MC) of a 6-kDa mature form of AM as seen from EC and VSMC. The
addition of AM into cultured cells dose-dependently increased cAMP
production and potently inhibited PDGF-stimulated thymidine incorpo-
ration. Pretreatment with the monoclonal antibody completely abolished
cAMP increase induced by exogenous AM. Moreover, antibody neutral-
ization of endogenously secreted AM in cultured EC, but not in MC or
VSMC, markedly (by ;70%) reduced basal cAMP production and
significantly (1.7-fold) enhanced DNA synthesis. These results indicate
that AM, acting as an autocrine/paracrine regulator, exerts an antiprolif-
erative action on EC and MC, and suggest its role as a local modulator of
endothelial and mesangial function.
Adrenomedullin, originally isolated from human pheochromo-
cytoma, is a 52-amino acid peptide with an intramolecular disul-
fide bond and an amidated C-terminus, and shows structural
homology with the potent vasodilator peptide, calcitonin gene-
related peptide (CGRP) [1]. Adrenomedullin (AM) elicits a
potent, long-lasting hypotensive effect comparable to CGRP [1],
mainly by stimulating cAMP production in target tissues via the
putative receptors shared with CGRP and those specific for AM
[1–6]. Structure-activity relationship studies revealed that the ring
structure formed by a disulfide bond and the C-terminal amida-
tion are critical for receptor binding and cAMP production [7].
When administered intrarenally, AM exerts potent natriuretic and
vasodilatory actions [8, 9]. Tissue distribution studies have shown
that AM is synthesized in various tissues including the adrenal
gland, kidney, lung, and heart [10, 11]. These tissues are rich in
AM receptors as well [4], suggesting that AM may act as a local
hormone. AM is also present in plasma [12], and using cultured
cells, it has been shown to be secreted from endothelial cells (EC)
and vascular smooth muscle cells (VSMC) [13, 14]. The functional
significance of AM, however, remains to be elucidated.
In the present study, we have developed a monoclonal antibody
against the ring structure of AM. Using this antibody, we estab-
lished a specific and sensitive radioimmunoassay (RIA) for AM,
and revealed its secretion not only from endothelial cells (EC)
and VSMC but also from mesangial cells (MC). Furthermore, we
examined the effects of neutralizing AM endogenously produced
by cultured cells, and found that AM, acting as an autocrine
regulator, plays an important role in controlling the basal cAMP
production and proliferation of the endothelium.
METHODS
Peptides
Fragment peptides of human AM (hAM), hAM (1-15), hAM
(15-31), and hAM (27-52) were synthesized by the solid phase
method and purified by reverse-phase high performance liquid
chromatography. Human adrenomedullin (hAM), rat AM (rAM),
hAM (22–52) (an AM receptor antagonist), human calcitonin
gene-related peptide (hCGRP)-I, and hCGRP (8-37) (a CGRP1
receptor antagonist) were purchased from Peptide Institute (Osa-
ka, Japan). Platelet-derived growth factor (PDGF)-BB was from
Becton Dickinson Labware (Bedford, MA, USA).
Preparation and characterization of monoclonal antibody
Human adrenomedullin (15-31) (3.0 mg) was conjugated to
bovine thyroglobulin (10.3 mg; Sigma, St. Louis, MO, USA) using
the carbodiimide coupling procedure [15]. Ten BALB/c mice were
immunized with subcutaneous injections of the conjugate contain-
ing 30 mg of the peptide emulsified in complete Freund’s adjuvant
(Difco, Detroit, MI, USA) over a period of five months at two to
three week intervals. Elevation of antibody titer screened by RIA
was observed in four mice, and the one with highest response
(final dilution, 1:25,000) was selected for cell fusion. Fusion of
spleen cells with mouse myeloma cells X63-Ag8.653 was per-
formed using 50% polyethylene glycol 4000 (Merck, Darmstadt,
Germany) as described [16]. Hybridomas were screened for
antibody production by the RIA, cloned by limiting dilution and
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expanded intraperitoneally in BALB/c mice. Isotyping of the
monoclonal antibody was performed by the Western blot tech-
nique (Mouse Monoclonal Isotyping Kit; Amersham, Bucking-
hamshire, UK). Binding affinity was analyzed by a Scatchard plot
using the RIA for AM.
Radioimmunoassay for adrenomedullin
Human adrenomedullin (15-31) was radioiodinated by the
chloramine T method as previously described [15]. The specific
activity of 125I-hAM (15–31) ranged from 600 to 900 mCi/mg. The
monoclonal antibody named KY-AM-I (final dilution of ascites,
1:7.5 3 105) was incubated with either standard hAM or samples
in 200 ml of assay buffer (50 mM phosphate buffer, pH 7.4,
containing 0.5% gelatin (Merck), 0.1% Triton X-100, 1 mM
Na2EDTA, 0.2 mM L-cystine, and 0.1% NaN3) for 24 hours at 4°C.
Then, 50 ml of 125I-hAM (15-31) (approximately 10,000 cpm) was
added and the mixture was further incubated for 16 hours at 4°C.
Bound and free ligands were separated by adding 1.0 ml of
suspension of dextran-coated charcoal consisting of 400 mg of
Norit SX Plus (Norit, the Netherlands) and 40 mg of Dextran
T-70 (Pharmacia, Uppsala, Sweden) in 100 ml of 50 mM phos-
phate buffer, pH 7.4, containing 0.1% NaN3 [15].
Cell culture
Bovine aortic EC and rat aortic VSMC were prepared from
explants as previously reported [17] and used at passages 10 to 15
in Dulbecco’s modified Eagle’s medium (DMEM) containing
10% fetal calf serum (FCS). Cells grown to confluence in 100-mm
dishes were washed twice with phosphate-buffered saline (PBS)
and incubated at 37°C for indicated time in DMEM containing
0.1% bovine serum albumin (BSA). Rat MC were prepared from
the glomeruli isolated from 20-week-old male Wistar rats by
differential sieving [17, 18] and used at passages 6 to 10 main-
tained in RPMI 1640 containing 10% FCS. Confluent MC were
washed twice with PBS and made quiescent by incubating in
DMEM/F-12 supplemented with 10 mg/ml insulin, 10 mg/ml
transferrin, 10 ng/ml selenium, and 0.1% BSA [19]. After incuba-
tion, conditioned media were condensed using a Sep-Pak C18
cartridge as described [13–15], and the dried material was dis-
solved in the RIA buffer and subjected to RIA for AM.
High-performance gel permeation chromatography
High-performance gel permeation chromatography (HP-GPC)
was performed on a TSK-GEL G2000 SW column (7.5 3 600 mm;
Toyo Soda, Tokyo, Japan), eluted with 10 mM trifluoroacetic acid
containing 0.3 M sodium chloride and 30% acetonitrile as a
solvent, as previously described [15]. The flow rate was 0.3 ml/min
and the fraction volume was 0.36 ml.
cAMP measurement
Basal and AM-stimulated cAMP production in the cells was
measured by RIA as described with slight modification [17, 20]. In
brief, cultured EC, VSMC or MC grown to confluence in 24-well
plates were washed twice with serum-free DMEM and preincu-
bated for 20 minutes at 37°C in 400 ml DMEM containing 0.1%
BSA and 0.5 mM isobutylmethylxanthine (IBMX; Sigma). Rat AM
dissolved in 100 ml of the same medium or vehicle was added to
the culture (final concentrations, 10211 to 1027 M) and cells were
further incubated for 30 minutes at 37°C. After incubation, 1 ml of
ice-cold ethanol was added to the culture to disrupt the cells and
the mixture was centrifuged at 15,000 3 g for 10 minutes at 4°C.
The supernatant was vacuum dried and the pellet dissolved in
assay buffer was subjected to RIA for cAMP after succinylation
using a commercial kit (Yamasa, Tokyo, Japan).
Neutralization experiment
The monoclonal antibody in ascites was purified with Affi-Gel
Protein A MAPS II kit (Bio-Rad, Richmond, CA, USA) [21] and
1 mg of purified monoclonal antibody was dissolved in 1 ml of
DMEM/0.1% BSA. Cells grown to confluence in 12-well plates
were washed twice with serum-free DMEM and preincubated for
10 minutes at 37°C in 400 ml DMEM/0.1% BSA/0.5 mM IBMX
with either 50 ml monoclonal antibody solution (final concentra-
tion, 100 mg/ml) or the same concentration of mouse IgG (Sigma).
Rat AM dissolved in 50 ml of DMEM/0.1% BSA was added to the
medium (final 1028 M) and cells were further incubated for 30
minutes at 37°C. After incubation, cAMP production was deter-
mined as above.
Proliferation studies
Cultured EC, VSMC or MC grown to confluence in 24-well
plates were washed with DMEM/F-12 and incubated in DMEM/
F-12/0.1% BSA with or without rAM (10212 to 1027 M) and
PDGF-BB (10 ng/ml) for 12 hours at 37°C. Then, 3H-thymidine
(Amersham) was added to the medium (final concentration, 10
mCi/ml) and cells were further incubated for four hours at 37°C.
After incubation, cells were washed twice with ice-cold PBS, and
the count of 3H-thymidine incorporated into the cells was mea-
sured [22].
For the neutralization experiment, cells grown to confluence in
24-well plates were washed with DMEM/F-12 and then preincu-
bated for four hours at 37°C in 500 ml DMEM/F-12/0.1% BSA.
Then, cells were washed and incubated for 24 hours in the
presence of either purified KY-AM-I (1 or 50 mg/ml), mouse IgG
(50 mg/ml), hAM (22–52) (1026 M), or hCGRP (8–37) (1026 M).
After incubation, cells were labeled with 3H-thymidine for six
hours and 3H-thymidine incorporation was measured.
Statistical analysis
Data were expressed as the mean 6 SEM. Statistical analysis was
performed using analysis of variance followed by Scheffe’s test.
P , 0.05 was considered significant.
RESULTS
Preparation and characterization of monoclonal antibody
After the fusion, three clones among 288 wells of hybridoma
gave a positive antibody response. After further culture and
cloning, one clone with highest response was selected for expan-
sion and characterization. The established monoclonal antibody,
named KY-AM-I, belonged to the IgG1 subclass. Analysis by a
Scatchard plot revealed high affinity for AM, with an association
constant (Ka) of 2.5 3 10
10 M21. Specificity of the monoclonal
antibody KY-AM-I in the RIA for AM is shown in Figure 1A.
Human adrenomedullin (15-31) showed an equimolar cross-
reactivity with standard hAM. There was no cross-reactivity
(, 0.01%) with hAM (1-15) or hAM (27-52), indicating that the
antibody recognizes the ring structure of AM.
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Radioimmunoassay for adrenomedullin
In the standard curve of the RIA for AM (Fig. 1), the minimal
detectable quantity was 1.0 fmol/tube, and the 50% binding
intercept was 8.0 fmol/tube. The cross-reactivities with rAM and
hCGRP-I were 100% and , 0.01%, respectively. The intra-assay
and interassay coefficients of variation were 4.2% (N 5 8) and
6.8% (N 5 8), respectively.
Adrenomedullin-like immunoreactivity (AM-LI) in culture
media
Serial dilution curves of culture media were parallel to the
standard curve (Fig. 1B). Table 1 shows time-dependent accumu-
lation of adrenomedullin-like immunoreactivity (AM-LI) in the
culture media. A significant amount of AM-LI (10210 to 10211 M)
was detected in the culture media conditioned with bovine aortic
EC and with rat aortic VSMC, at the level similar to that in
previous reports [13, 14]. AM-LI was also detected abundantly in
the culture media of rat MC, demonstrating the mesangial
secretion of AM at the level comparable to that from EC or
VSMC.
To assess the molecular form of AM-LI secreted from those
cells, HP-GPC analysis was performed (Fig. 2). A major compo-
nent of AM-LI in the culture supernatant of EC and VSMC
emerged at the position of 6 kDa corresponding to the elution
position of authentic AM (Fig. 2 A, B). A minor peak was
detected in the lower molecular weight range, suggesting its
degradation product(s). Using culture media of rat MC, an
essentially similar pattern was observed (Fig. 2C).
Effect of adrenomedullin on cAMP production
To examine whether AM acts on these cells of AM production,
cAMP levels were measured in cultured EC, VSMC and MC after
stimulation by exogenous AM. Addition of AM resulted in
dose-dependent increases of cAMP production in these cells (Fig.
3), with EC50 values of ;10
210 M in EC and MC, and ;1029 M in
VSMC.
Neutralization experiment
To further examine the hypothesis that AM acts on these cells
in an autocrine fashion, we performed in vitro neutralization
experiments with the established monoclonal antibody. Figure 4
shows the effects of pretreatment with KY-AM-I on basal and
AM-stimulated cAMP production in cultured EC. Addition of
rAM (1028 M) into cultured EC showed a threefold increase of
cAMP production, and administration of KY-AM-I completely
abolished this effect (2.72 6 0.21 vs. 0.63 6 0.08 pmol/105 cells,
P , 0.001; Fig. 4). Pretreatment with KY-AM-I in cultured
VSMC or MC also effectively abolished cAMP increase induced
by exogenous AM (data not shown), indicating that this mono-
clonal antibody acts as a neutralizing antibody. Under this condi-
tion, even in the unstimulated state, neutralization with KY-AM-I
of endogenously secreted AM in cultured EC resulted in signifi-
cant (by ;70%) reduction of basal cAMP production (1.05 6 0.14
vs. 0.35 6 0.04 pmol/105 cells, P , 0.01), whereas control IgG did
not affect cAMP levels (Fig. 4). These results strongly indicate
Fig. 1. A typical standard curve of adrenomedullin (AM) and cross-
reactivity profiles of its related peptides (A) and dilution curves of culture
media (B) in the radioimmunoassay (RIA) for AM with a monoclonal
antibody KY-AM-I. Abbreviations and symbols in A are: (F) hAM, human
AM; (E) rAM, rat AM; () hAM (15-31); () hAM (1-15); (f) hAM
(27-52); (M) hCGRP-I. In B, symbols and abbreviations are: (E) bEC,
bovine endothelial cells; () rVSMC, rat vascular smooth muscle cells;
(M) rMC, rat mesangial cells.
Table 1. Accumulation of adrenomedullin (AM)-like immunoreactivity
in culture media of bovine endothelial cells (bEC), rat vascular smooth
muscle cells (rVSMC), and rat mesangial cells (rMC)
AM, fmol/105 cells
12 hrs 24 hrs 36 hrs
bEC 10.9 6 2.3 21.8 6 4.7 28.3 6 5.0
rVSMC 3.9 6 0.8 12.1 6 2.5 16.4 6 2.4
rMC 4.8 6 0.6 6.2 6 1.2 6.4 6 0.8
Values are expressed as the mean 6 SEM (N 5 4).
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that AM, acting in an autocrine manner, has a significant contri-
bution to maintaining the basal cAMP production in cultured EC.
The inhibitory effect of neutralizing AM on basal cAMP produc-
tion was not observed in cultured VSMC (0.78 6 0.14 vs. 0.84 6
0.06 pmol/105 cells) or in MC (0.83 6 0.09 vs. 0.79 6 0.08
pmol/105 cells), suggesting that the contribution of endogenously
secreted AM to their basal cAMP levels in these cells was less
significant than in cultured EC.
Proliferation studies
To further explore the biological actions exerted by AM, we
examined effects on cell proliferation. Addition of AM into
cultured cells inhibited PDGF-stimulated DNA synthesis in a
dose-dependent manner (Fig. 5). The inhibitory effects of AM at
10210 M were 284.0 6 8.4%, 241.8 6 9.7%, and 221.1 6 8.3%,
respectively, in cultured EC, VSMC and MC.
Next, to investigate the possible autocrine role of AM in cell
growth, we examined effects of neutralization using the AM
monoclonal antibody in these cells. Figure 6 shows the effect of
pretreatment with KY-AM-I on DNA synthesis in cultured EC.
Neutralization with KY-AM-I of endogenously secreted AM in
EC significantly increased basal 3H-thymidine uptake dose-depen-
dently (142.1 6 8.1% and 169.5 6 4.0% at 1 and 50 mg/ml
KY-AM-I, respectively, of the basal level, P , 0.01), whereas
Fig. 2. Typical high performance-gel permeation chromatography (HP-GPC) profiles of adrenomedullin-like immunoreactivity (AM-LI) in the culture
supernatant of bovine endothelial cells (EC; A), rat vascular smooth muscle cells (VSMC; B), and rat mesangial cells (MC; C). Arrows denote elution
positions of a series of myoglobins of a polypeptide molecular weight calibration kit (Pharmacia), void volume (Vo) and total volume (Vt). The elution
position of synthetic AM is also indicated.
Fig. 3. Adrenomedullin (AM)-stimulated increase of cAMP production in cultured bovine endothelial cells (EC; A), rat vascular smooth muscle cells
(VSMC; B), and rat mesangial cells (MC; C). Values are expressed as the mean 6 SEM (N 5 4). B is basal.
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control IgG showed no effect. Neutralization of AM in cultured
MC or VSMC did not affect significantly in their basal DNA
synthesis (data not shown). This stimulatory effect of the AM
monoclonal antibody on EC growth was mimicked by pretreat-
ment with hAM (22–52), a putative AM receptor antagonist
(167.8 6 8.9% at 1026 M) but not hCGRP (8–37), a putative
CGRP1 receptor antagonist (107.1 6 4.2% at 10
26 M). This
suggests that the effects of AM on EC may be mediated mainly via
the putative receptor specific for AM.
DISCUSSION
In the present study, we prepared a specific, high-affinity
monoclonal antibody against AM. The antibody KY-AM-I is
directed against the ring structure of AM, which is essential for
exerting its biological activity [7]. The established RIA with this
antibody recognizes AM of human, rat and bovine forms with high
sensitivity, and detects its native form with the ring structure.
Using this RIA, we detected 6 kDa AM-LI in the culture media
conditioned with rat MC, at the level almost comparable to that
from EC or VSMC (Table 1) [13, 14]. The minor peaks in
HP-GPC (Fig. 2 A, C) may represent natural or artifactual
fragments of AM whose nature remains to be characterized
[12–14]. Adrenomedullin has so far been demonstrated in the
kidney [1, 8, 10–12] and is immunohistochemically localized in
glomeruli and tubules [8]; the precise localization of AM produc-
tion in the kidney, however, has not been clarified. The present
study showed that the mesangium, in addition to the vascular
endothelium, should be one probable source of AM produced in
the kidney. Locally produced AM may act to modulate glomerular
function, and indeed, intrarenal administration of AM has been
shown to exert potent natriuretic and vasorelaxing activities [8, 9].
Moreover, AM inhibits MC proliferation stimulated by mitogens
such as PDGF (Fig. 5C) [23]. Proliferation of MC with mesangial
matrix expansion is a characteristic feature of many glomerular
diseases, and a variety of growth factors, cytokines and vasoactive
substances may mediate this disease process [24]. The synthesis of
AM in the mesangium may, as in EC or VSMC [13, 14], be
regulated by these hormones and cytokines, thereby potentially
modulating mesangial proliferation and function in various patho-
logical conditions. Taken together, it is conceivable that AM may
play a role in the regulation of glomerular function through an
autocrine/paracrine mechanism.
The present study revealed that AM potently inhibits prolifer-
ation of cultured EC (Fig. 5A). This effect is likely to be mediated
mainly via the cAMP pathway to inhibit the mitogen-activated
protein kinase cascade as reported in MC and VSMC [23, 25, 26].
The antigrowth effect of AM in EC observed here, however, was
more potent than in other cell types whereas stimulation of cAMP
production was less remarkable (Figs. 3 and 5), suggesting that
other intracellular mechanisms such as the nitric oxide pathway
may be partly involved in this particular cell type [3, 9]. In other
cell types such as tumor cells, AM has been shown to stimulate
cell proliferation in a cAMP-dependent manner [27, 28]. The
reason for the difference causing these apparently contradictory
results on cell proliferation is currently unclear, but the dual
function of cAMP has been already known depending upon the
relative cellular amounts of two distinct cAMP-dependent protein
kinase A isoforms: RI with growth promotion and RII with growth
inhibition [29].
In the present study, we demonstrated that neutralization with
the AM monoclonal antibody markedly (by ;70%) reduced the
basal cAMP production in cultured EC (Fig. 4). Neutralization
experiment also revealed the significance of AM as an autocrine
regulator of EC growth (Fig. 6). Whether this is true with the in
vivo situation, and with various pathological conditions in which
AM secretion is augmented [30], remain to be clarified. Neutral-
ization of AM in MC or VSMC did not directly affect their cAMP
levels or DNA synthesis, but the potent inhibitory effect of
exogenous AM on their growth still suggests AM as a paracrine
growth regulator in these cells. In general, these cells produce a
wide variety of factors capable of promoting or inhibiting growth
in an autocrine or paracrine fashion, and it has been proposed
that many abnormalities encountered in diabetic renal and vascu-
lar complications could be due to the altered EC-MC and
EC-VSMC interactions [31, 32]. Furthermore, we have recently
demonstrated that shear stress, one of the potent modifiers of
vascular remodeling, augments AM expression in cultured EC
[33]. From these results, it seems likely that AM, together with
C-type natriuretic peptide [34], could represent one of the major
peptide-type endothelium-derived relaxing factors, participating
in the modulation of vascular and mesangial function through
paracrine interactions.
In conclusion, we developed a high-affinity, neutralizing mono-
clonal antibody against AM, which should provide a useful tool to
further explore the functional role of AM. Moreover, the findings
on the autocrine role of AM in modulating endothelial growth,
together with the mesangial secretion of AM, point toward the
need for investigative studies to determine its significance in
various pathological conditions, such as diabetic, atherosclerotic,
and hypertensive renal and vascular complications.
Fig. 4. Effects of pretreatment with the monoclonal antibody KY-AM-I
(f) or control IgG (o) on basal and AM-stimulated cAMP production in
cultured bovine endothelial cells (EC; M). Values are expressed as the
mean 6 SEM (N 5 6). *P , 0.01, **P , 0.001.
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APPENDIX
Abbreviations used in this article are: AM, adrenomedullin; AM-LI,
adrenomedullin-like immunoreactivity; bEC, bovine endothelial cells;
BSA, bovine serum albumin; CGRP, calcitonin gene-related peptide;
DMEM, Dulbecco’s modified Eagle’s medium; EC, endothelial cells; FCS,
fetal calf serum; hAM, human adrenomedullin; hCGRP-I, human calci-
tonin gene-related peptide; HP-GPC, high-performance gel permeation
chromatography; IBMX, isobutylmethylxanthine; MC, mesangial cells;
PBS, phosphate buffered saline; PDGF, platelet-derived growth factor;
rAM, rat AM; RIA, radioimmunoassay; rMC, rat mesangial cells; rVSMC,
rat vascular smooth muscle cells; VSMC, vascular smooth muscle cells.
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